NASDAQ:IONS Ionis Pharmaceuticals (IONS) Stock Price, News & Analysis $32.78 +1.07 (+3.37%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$33.06 +0.28 (+0.87%) As of 05/2/2025 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Ionis Pharmaceuticals Stock (NASDAQ:IONS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Ionis Pharmaceuticals alerts:Sign Up Key Stats Today's Range$32.01▼$33.2050-Day Range$25.51▼$34.3952-Week Range$23.95▼$52.34Volume1.89 million shsAverage Volume1.55 million shsMarket Capitalization$5.21 billionP/E RatioN/ADividend YieldN/APrice Target$56.67Consensus RatingModerate Buy Company OverviewIonis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.Read More… Ionis Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks88th Percentile Overall ScoreIONS MarketRank™: Ionis Pharmaceuticals scored higher than 88% of companies evaluated by MarketBeat, and ranked 156th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingIonis Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.65, and is based on 12 buy ratings, 6 hold ratings, and 1 sell rating.Amount of Analyst CoverageIonis Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Ionis Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Ionis Pharmaceuticals are expected to grow in the coming year, from ($3.50) to ($2.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ionis Pharmaceuticals is -10.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ionis Pharmaceuticals is -10.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIonis Pharmaceuticals has a P/B Ratio of 8.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.41% of the float of Ionis Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverIonis Pharmaceuticals has a short interest ratio ("days to cover") of 8.3.Change versus previous monthShort interest in Ionis Pharmaceuticals has recently increased by 9.07%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIonis Pharmaceuticals does not currently pay a dividend.Dividend GrowthIonis Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG3.0 / 5Environmental Score-3.58 Percentage of Shares Shorted9.41% of the float of Ionis Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverIonis Pharmaceuticals has a short interest ratio ("days to cover") of 8.3.Change versus previous monthShort interest in Ionis Pharmaceuticals has recently increased by 9.07%, indicating that investor sentiment is decreasing significantly. News and Social Media3.4 / 5News Sentiment1.18 News SentimentIonis Pharmaceuticals has a news sentiment score of 1.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 29 news articles for Ionis Pharmaceuticals this week, compared to 8 articles on an average week.Search Interest3 people have searched for IONS on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Ionis Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Ionis Pharmaceuticals insiders have sold 211.19% more of their company's stock than they have bought. Specifically, they have bought $477,900.00 in company stock and sold $1,487,181.00 in company stock.Percentage Held by InsidersOnly 2.71% of the stock of Ionis Pharmaceuticals is held by insiders.Percentage Held by Institutions93.86% of the stock of Ionis Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ionis Pharmaceuticals' insider trading history. Receive IONS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ionis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address IONS Stock News HeadlinesMichael R. Hayden Acquires 15,000 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) StockMay 3 at 5:13 AM | insidertrades.comInsider Selling: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Sells 680 Shares of StockApril 18, 2025 | insidertrades.comTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what could be the biggest wealth opportunity since Bitcoin's early days.May 4, 2025 | Crypto 101 Media (Ad)Ionis Pharmaceuticals (NASDAQ:IONS) Shares Gap Up After Earnings BeatMay 2 at 1:11 AM | americanbankingnews.com7IONS : The Analyst Verdict: Ionis Pharmaceuticals In The Eyes...May 1 at 3:06 PM | benzinga.comIonis Pharmaceuticals Inc (IONS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...May 1 at 5:02 AM | finance.yahoo.comIonis Pharmaceuticals misses Q1 revenue estimates, raises full-year outlookApril 30, 2025 | investing.comIonis Pharmaceuticals, Inc. (IONS) Q1 2025 Earnings Call TranscriptApril 30, 2025 | seekingalpha.comSee More Headlines IONS Stock Analysis - Frequently Asked Questions How have IONS shares performed this year? Ionis Pharmaceuticals' stock was trading at $34.96 at the beginning of 2025. Since then, IONS stock has decreased by 6.2% and is now trading at $32.78. View the best growth stocks for 2025 here. How were Ionis Pharmaceuticals' earnings last quarter? Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) released its quarterly earnings results on Wednesday, April, 30th. The company reported ($0.93) earnings per share for the quarter, topping analysts' consensus estimates of ($1.07) by $0.14. The firm's quarterly revenue was up 10.9% on a year-over-year basis. Read the conference call transcript. Who are Ionis Pharmaceuticals' major shareholders? Ionis Pharmaceuticals' top institutional shareholders include Teacher Retirement System of Texas (0.31%), Sovran Advisors LLC (0.21%), Rhumbline Advisers (0.12%) and Sumitomo Mitsui Trust Group Inc. (0.09%). Insiders that own company stock include Brett P Monia, Elizabeth L Hougen, Richard S Geary, B Lynne Parshall, C Frank Bennett, Brian Birchler, Patrick R O'neil, Michael R Hayden, Eric Swayze, Eugene Schneider, Onaiza Cadoret-Manier, Joseph Baroldi, Joseph Klein III and Allene M Diaz. View institutional ownership trends. How do I buy shares of Ionis Pharmaceuticals? Shares of IONS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ionis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ionis Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Arista Networks (ANET), Adobe (ADBE) and CrowdStrike (CRWD). Company Calendar Last Earnings4/30/2025Today5/03/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:IONS CIK874015 Webwww.ionispharma.com Phone(760) 931-9200Fax760-603-2700Employees800Year FoundedN/APrice Target and Rating Average Stock Price Target$56.67 High Stock Price Target$77.00 Low Stock Price Target$37.00 Potential Upside/Downside+72.9%Consensus RatingModerate Buy Rating Score (0-4)2.65 Research Coverage20 Analysts Profitability EPS (Most Recent Fiscal Year)($2.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-366,290,000.00 Net Margins-64.25% Pretax Margin-65.25% Return on Equity-100.05% Return on Assets-15.70% Debt Debt-to-Equity Ratio2.12 Current Ratio8.47 Quick Ratio8.82 Sales & Book Value Annual Sales$705.14 million Price / Sales7.39 Cash FlowN/A Price / Cash FlowN/A Book Value$3.70 per share Price / Book8.86Miscellaneous Outstanding Shares158,965,000Free Float153,618,000Market Cap$5.21 billion OptionableOptionable Beta0.29 Social Links Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:IONS) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | SponsoredWill May start the next "Great Depression?"You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...Behind the Markets | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ionis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ionis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.